Business Context and Reporting Period
This Form 8-K Current Report was filed by EyeGate Pharmaceuticals, Inc. on June 27, 2016. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of securities. Note: The request metadata references "Kiora Pharmaceuticals Inc," but the filing text explicitly identifies the registrant as "EyeGate Pharmaceuticals, Inc."
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement with a single institutional investor. Key transaction metrics include:
- Expected Gross Proceeds: Approximately $3.77 million.
- Expected Net Proceeds: Approximately $3.4 million (after deducting placement agent fees, expenses, and excluding warrant exercise proceeds).
- Securities Issued:
- 441,000 shares of Common Stock at $2.25 per share.
- 2,776.5 shares of Series A Convertible Preferred Stock at $1,000 per share (convertible into approx. 1.23 million Common Shares at $2.25/share).
- Warrants to purchase 837,500 shares of Common Stock at an exercise price of $3.50 per share, exercisable for five years starting six months post-issuance.
- Placement Agent Fees: 7% of aggregate gross proceeds plus warrants to purchase up to 2% of the aggregate shares sold, plus a $50,000 reimbursement for legal fees.
Material Changes and Use of Proceeds
This filing represents a material change in the Company's capital structure through the issuance of new equity and warrants. The Company intends to use the net proceeds to:
- Support operations and working capital.
- Fund clinical trials.
- Pursue research and development efforts.
- Potentially acquire or in-license products, product candidates, or technologies (though none are currently contemplated).
The filing does not provide specific revenue, profit, cash flow, or debt metrics for the reporting period, as this is a transactional filing rather than a periodic financial report.
Guidance, Risks, and Unusual Items
Management Commentary: The Company has not yet determined the specific allocation of net proceeds among the intended uses. The closing is expected on or about June 30, 2016, subject to customary conditions.
Risks and Contingencies:
- Dilution: The issuance of Common Stock, convertible Preferred Stock, and Warrants will result in significant dilution to existing shareholders.
- Ownership Limitations: Conversion of Preferred Stock and exercise of Warrants are subject to beneficial ownership limitations (generally capped at 4.99%, potentially 9.99%).
- Liquidation Preference: Series A Preferred Stock holders have a nominal liquidation preference of $0.01 per share senior to Common Stock.
- Unregistered Sales: Warrants were sold in reliance on Section 4(a)(2) and Rule 506 exemptions, meaning they are not registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the closing of the transaction on or about June 30, 2016.
- Confirm the actual net proceeds received after all fees and expenses.
- Review the filed Certificate of Designation (Exhibit 3.1) for full terms of the Series A Preferred Stock.
- Monitor future filings for the specific allocation of funds to clinical trials versus general corporate purposes.
- Assess the impact of the new share count (Common Stock + Convertible Preferred + Warrants) on earnings per share and ownership dilution.